General Biologicals Displays CLIA and Molecular Diagnostic Solutions at WHX Labs Dubai

D50, February 10–13 at the Dubai World Trade Centre.

In molecular diagnostics, the company is demonstrating the AIO M160 fully automated system, which integrates nucleic acid extraction, amplification, and detection within a single platform. The system is designed to deliver a sample-to-result workflow, reducing manual intervention while improving operational efficiency. The compact system is built for efficiency, processing up to 16 samples simultaneously with a total turnaround time of under 2.5 hours. It features a high multiplexing capability with five qPCR channels, allowing for both qualitative and quantitative results from various sample types like whole blood, plasma, and tissue.

GBC is also showcasing its chemiluminescence immunoassay (CLIA) system, developed for laboratories of varying sizes. The platform includes the GBC CL i-120 CLIA System, an automated analyzer that optimizes workflows for protein and antibody detection. This technology is applied across a wide range of health targets, including thyroid function, tumor markers, and infectious disease screening.

Among the other featured technologies is the CellBio™ CTC circulating tumor cell detection platform, a non-invasive system designed to isolate circulating tumor cells (CTCs) from blood samples. The platform supports multi-level molecular analysis of DNA, RNA, and proteins, enabling applications in early cancer detection, therapy monitoring, and precision oncology research. The product lineup includes the CellBio™ a2000 for standard workflows and the CellBio™ FX10 for high-throughput laboratory environments. The platform preserves intact cell morphology, allowing for a wide range of downstream analyses including immunostaining, FISH, and NGS.

Live product demonstrations are being conducted at the booth, where attendees can learn more about the company’s technologies and discuss implementation and partnership opportunities.

Related Links:
General Biologicals Corporation